Literature DB >> 24760885

Protective properties of vaccinia virus-based vaccines: skin scarification promotes a nonspecific immune response that protects against orthopoxvirus disease.

Amanda D Rice1, Mathew M Adams1, Scott F Lindsey1, Daniele M Swetnam1, Brandi R Manning1, Andrew J Smith1, Andrew M Burrage1, Greg Wallace1, Amy L MacNeill2, Richard W Moyer3.   

Abstract

The process of vaccination introduced by Jenner generated immunity against smallpox and ultimately led to the eradication of the disease. Procedurally, in modern times, the virus is introduced into patients via a process called scarification, performed with a bifurcated needle containing a small amount of virus. What was unappreciated was the role that scarification itself plays in generating protective immunity. In rabbits, protection from lethal disease is induced by intradermal injection of vaccinia virus, whereas a protective response occurs within the first 2 min after scarification with or without virus, suggesting that the scarification process itself is a major contributor to immunoprotection. importance: These results show the importance of local nonspecific immunity in controlling poxvirus infections and indicate that the process of scarification should be critically considered during the development of vaccination protocols for other infectious agents.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24760885      PMCID: PMC4097768          DOI: 10.1128/JVI.00185-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Effect of IFN-gamma receptor gene deletion on vaccinia virus virulence.

Authors:  V Sroller; V Ludvíková; L Maresová; P Hainz; S Nĕmecková
Journal:  Arch Virol       Date:  2001       Impact factor: 2.574

2.  Risks and benefits of vaccinia vaccine use in the worldwide smallpox eradication campaign.

Authors:  F Fenner
Journal:  Res Virol       Date:  1989 Sep-Oct

3.  Attenuation of B5R mutants of rabbitpox virus in vivo is related to impaired growth and not an enhanced host inflammatory response.

Authors:  R J Stern; J P Thompson; R W Moyer
Journal:  Virology       Date:  1997-06-23       Impact factor: 3.616

Review 4.  Orthopoxvirus targets for the development of antiviral therapies.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Curr Drug Targets Infect Disord       Date:  2005-03

5.  Isolation and preliminary characterization of temperature-sensitive mutants of vaccinia virus.

Authors:  R C Condit; A Motyczka
Journal:  Virology       Date:  1981-08       Impact factor: 3.616

6.  Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus.

Authors:  R C Condit; A Motyczka; G Spizz
Journal:  Virology       Date:  1983-07-30       Impact factor: 3.616

7.  NYVAC: a highly attenuated strain of vaccinia virus.

Authors:  J Tartaglia; M E Perkus; J Taylor; E K Norton; J C Audonnet; W I Cox; S W Davis; J van der Hoeven; B Meignier; M Riviere
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

8.  CpG-DNA protects against a lethal orthopoxvirus infection in a murine model.

Authors:  D G Cerys Rees; Amanda J Gates; Michael Green; Lin Eastaugh; Roman A Lukaszewski; Kate F Griffin; Arthur M Krieg; Richard W Titball
Journal:  Antiviral Res       Date:  2005-02       Impact factor: 5.970

Review 9.  Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.

Authors:  Amanda D Rice; Mathew M Adams; Greg Wallace; Andrew M Burrage; Scott F Lindsey; Andrew J Smith; Daniele Swetnam; Brandi R Manning; Stacey A Gray; Bernhard Lampert; Scott Foster; Randall Lanier; Alice Robertson; George Painter; Richard W Moyer
Journal:  Viruses       Date:  2011-01       Impact factor: 5.048

10.  Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.

Authors:  J W Hooper; E Thompson; C Wilhelmsen; M Zimmerman; M Ait Ichou; S E Steffen; C S Schmaljohn; A L Schmaljohn; P B Jahrling
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more
  9 in total

1.  Pattern Recognition Receptors of Nucleic Acids Can Cause Sublethal Activation of the Mitochondrial Apoptosis Pathway during Viral Infection.

Authors:  Sylwia Gradzka-Boberda; Ian E Gentle; Georg Häcker
Journal:  J Virol       Date:  2022-09-07       Impact factor: 6.549

Review 2.  Imaging viral infection in vivo to gain unique perspectives on cellular antiviral immunity.

Authors:  Sophia M Vrba; Heather D Hickman
Journal:  Immunol Rev       Date:  2021-11-18       Impact factor: 10.983

3.  Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters.

Authors:  George Giorgi Babuadze; Hugues Fausther-Bovendo; Marc-Antoine deLaVega; Brandon Lillie; Maedeh Naghibosadat; Nariman Shahhosseini; Michael A Joyce; Holly A Saffran; D Lorne Tyrrell; Darryl Falzarano; Chandrika Senthilkumaran; Natasha Christie-Holmes; Steven Ahn; Scott D Gray-Owen; Arinjay Banerjee; Samira Mubareka; Karen Mossman; Chanel Dupont; Jannie Pedersen; Mark-Alexandre Lafrance; Gary P Kobinger; Robert Kozak
Journal:  NPJ Vaccines       Date:  2022-04-26       Impact factor: 9.399

4.  Low-Temperature Multiple Micro-Dispensing on Microneedles for Accurate Transcutaneous Smallpox Vaccination.

Authors:  Sang-Gu Yim; Yun-Ho Hwang; Seonyeong An; Keum-Yong Seong; Seo-Yeon Kim; Semin Kim; Hyeseon Lee; Kang-Oh Lee; Mi-Young Kim; Dokeun Kim; You-Jin Kim; Seung-Yun Yang
Journal:  Vaccines (Basel)       Date:  2022-04-04

5.  Development of potent class II transactivator gene delivery systems capable of inducing de novo MHC II expression in human cells, in vitro and ex vivo.

Authors:  M L Palma; P Duangkhae; B Douradinha; I F T Viana; P O Rigato; R Dhalia; R B Mailliard; S M Barratt-Boyes; E J M Nascimento; T M Oshiro; A J da Silva Duarte; E T A Marques
Journal:  Gene Ther       Date:  2017-04-17       Impact factor: 4.184

6.  Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.

Authors:  Clement A Meseda; Vajini Atukorale; Jordan Kuhn; Falko Schmeisser; Jerry P Weir
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

7.  Recombinant Myxoma Virus Expressing Walleye Dermal Sarcoma Virus orfC Is Attenuated in Rabbits.

Authors:  Laura V Ashton; Sandra L Quackenbush; Jake Castle; Garin Wilson; Jasmine McCoy; Mariah Jordan; Amy L MacNeill
Journal:  Viruses       Date:  2020-05-08       Impact factor: 5.048

8.  Phase-out of smallpox vaccination and the female/male HIV-1 prevalence ratio: an ecological study from Guinea-Bissau.

Authors:  Andreas Rieckmann; Marie Villumsen; Bo Langhoff Hønge; Signe Sørup; Amabelia Rodrigues; Zacarias Jose da Silva; Hilton Whittle; Christine Benn; Peter Aaby
Journal:  BMJ Open       Date:  2019-10-30       Impact factor: 2.692

Review 9.  Skin Viral Infections: Host Antiviral Innate Immunity and Viral Immune Evasion.

Authors:  Vivian Lei; Amy J Petty; Amber R Atwater; Sarah A Wolfe; Amanda S MacLeod
Journal:  Front Immunol       Date:  2020-11-06       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.